BenevolentAI
proven to enhance drug discovery disease agnostic modality agnostic built for scale we can work on any therapeutic area due to the breadth and diversity of our data foundations the benevolent platform can be applied to antibody and biologic targets in addition to small molecule targets our scalable and versatile platform can support multiple in house drug programmes and commercial collaborations accelerates discovery by combining our platform and wet lab facilities we accelerate discovery and reduce discovery and development identifies novel targets our predictive tools can surface targets that have never been considered for a disease before potential to increase probability of success by building higher con hypotheses in the stages of drug discovery we aim to reduce costly failures down the line | BenevolentAI
Company
Deck Type
Sector
Industry
Deck date
January 2023
Slide
15 of 29
Similar slides by BenevolentAI
See diffirences between slides (animation)
Results
March 2023
proven to enhance drug discovery disease agnostic modality agnostic built for scale we can work on any therapeutic area due to the breadth and diversity of our data foundations the benevolent platform can be applied to antibody and biologic targets in addition to small molecule targets our scalable and versatile platform can support multiple in house drug programmes and commercial collaborations accelerates discovery by combining our platform and wet lab facilities we accelerate discovery and reduce discovery and development identifies novel targets our predictive tools can surface targets that have never been considered for a disease before potential to increase probability of success by building higher con hypotheses in the stages of drug discovery we aim to reduce costly failures down the line | BenevolentAI
Related slides by other companies
AbCellera
Results
November 2022
i a a uts of conventional drug discovery cell engager platform channels platform | AbCellera
Absci
IPO
July 2021
integrated drug creation platform | Absci
Absci
IPO
July 2021
integrated drug creation platform | Absci
Absci
IPO
July 2021
simultaneous drug discovery and cell development nee one gee candidate | Absci
Other recent decks by BenevolentAI
See all presentations (10 decks)
Results
March 2024
Investor Conference
January 2024
Investor Presentation
May 2023
Results
March 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io